モノメチルアウリスタチンE
↑ Statement on a nonproprietary name adopted by the USAN Council: Vedotin
1 2 Doronina, Svetlana O.; Toki, Brian E.; Torgov, Michael Y.; Mendelsohn, Brian A.; Cerveny, Charles G.; Chace, Dana F.; DeBlanc, Ron L.; Gearing, R. Patrick et al. (2003-07). “Development of potent monoclonal antibody auristatin conjugates for cancer therapy” (英語). Nature Biotechnology 21 (7): 778–784. doi:10.1038/nbt832. ISSN 1546-1696. https://www.nature.com/articles/nbt832.
↑ Dosio, F.; Brusa, P.; Cattel, L. (2011). “Immunotoxins and Anticancer Drug Conjugate Assemblies: The Role of the Linkage between Components”. Toxins 3 (12): 848–883.
↑ Medical News Today: CuraGen Announces Expansion Of CR011-vcMMAE Phase II Trial In Advanced Breast Cancer
↑ NCI Drug Dictionary: Glembatumumab vedotin
↑ Pereira, DS; Guevara, CI; Jin, L; Mbong, N; Verlinsky, A; Hsu, SJ; Aviña, H; Karki, S et al. (2015). “AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML”. Mol Cancer Ther 14 (7): 1650–60. doi:10.1158/1535-7163.MCT-15-0067. PMC 4557793. PMID 25934707. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4557793/.